Literature DB >> 2254756

Biological characterization of recombinant vaccinia viruses in mice infected by the respiratory route.

J D Williamson1, R W Reith, L J Jeffrey, J R Arrand, M Mackett.   

Abstract

A murine model based on infection by the respiratory route has been used to study the pathogenesis of recombinant vaccinia viruses. The neurovirulent Western Reserve (WR) strain and the Wyeth smallpox vaccine strain were used as vectors. Recombinant viruses were constructed by insertion of the Epstein-Barr virus membrane glycoprotein 340 gene into the thymidine kinase (TK) gene of each vaccinia virus. Intranasal inoculation of DBA/2 mice with 10(6) pock-forming units (pk.f.u.) of the WR strain was lethal but mice survived similar infection with the WR recombinant virus. Each virus was recovered from lung, blood and brain but, unlike wild-type virus, the recombinant virus was subsequently cleared. No deaths occurred after similar infection with the Wyeth strain or the Wyeth recombinant virus. There was limited growth of the Wyeth strain in the respiratory tract, low levels of virus in the blood and only sporadic recovery in brain extracts. The Wyeth recombinant virus was cleared rapidly with little viraemia or detectable infection of the central nervous system. No phenotypic character determined in vitro could be related consistently to the virulence of wild-type and recombinant viruses. Although the lethal character of the WR strain was affected by its TK+ phenotype, mice survived infection by intranasal inoculation with 10(6) pk.f.u. of WR TK+ recombinant viruses which either expressed the human interleukin 2 gene or had a deficient vaccinia virus growth factor gene.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2254756     DOI: 10.1099/0022-1317-71-11-2761

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  66 in total

1.  Identification of second-site mutations that enhance release and spread of vaccinia virus.

Authors:  Ehud Katz; Elizabeth Wolffe; Bernard Moss
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

2.  Mutations in the vaccinia virus A33R and B5R envelope proteins that enhance release of extracellular virions and eliminate formation of actin-containing microvilli without preventing tyrosine phosphorylation of the A36R protein.

Authors:  Ehud Katz; Brian M Ward; Andrea S Weisberg; Bernard Moss
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

3.  Lister strain vaccinia virus with thymidine kinase gene deletion is a tractable platform for development of a new generation of oncolytic virus.

Authors:  J Hughes; P Wang; G Alusi; H Shi; Y Chu; J Wang; V Bhakta; I McNeish; A McCart; N R Lemoine; Y Wang
Journal:  Gene Ther       Date:  2015-04-16       Impact factor: 5.250

4.  Chimpanzee/human mAbs to vaccinia virus B5 protein neutralize vaccinia and smallpox viruses and protect mice against vaccinia virus.

Authors:  Zhaochun Chen; Patricia Earl; Jeffrey Americo; Inger Damon; Scott K Smith; Yi-Hua Zhou; Fujuan Yu; Andrew Sebrell; Suzanne Emerson; Gary Cohen; Roselyn J Eisenberg; Juraj Svitel; Peter Schuck; William Satterfield; Bernard Moss; Robert Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-25       Impact factor: 11.205

5.  The vaccinia virus superoxide dismutase-like protein (A45R) is a virion component that is nonessential for virus replication.

Authors:  F Almazán; D C Tscharke; G L Smith
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

6.  A conserved poxvirus NlpC/P60 superfamily protein contributes to vaccinia virus virulence in mice but not to replication in cell culture.

Authors:  Tatiana G Senkevich; Linda S Wyatt; Andrea S Weisberg; Eugene V Koonin; Bernard Moss
Journal:  Virology       Date:  2008-02-20       Impact factor: 3.616

7.  A comparison of the effect of molluscum contagiosum virus MC159 and MC160 proteins on vaccinia virus virulence in intranasal and intradermal infection routes.

Authors:  Sunetra Biswas; Geoffrey L Smith; Edward J Roy; Brian Ward; Joanna L Shisler
Journal:  J Gen Virol       Date:  2018-02       Impact factor: 3.891

8.  Poxvirus decapping enzymes enhance virulence by preventing the accumulation of dsRNA and the induction of innate antiviral responses.

Authors:  Shin-Wu Liu; George C Katsafanas; Ruikang Liu; Linda S Wyatt; Bernard Moss
Journal:  Cell Host Microbe       Date:  2015-03-11       Impact factor: 21.023

9.  Genetically stable and fully effective smallpox vaccine strain constructed from highly attenuated vaccinia LC16m8.

Authors:  Minoru Kidokoro; Masato Tashiro; Hisatoshi Shida
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-07       Impact factor: 11.205

10.  Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge.

Authors:  Linda S Wyatt; Patricia L Earl; Leigh Anne Eller; Bernard Moss
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-11       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.